Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | USP8 | P40818 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31046888 | 0.90 | USP2 (0.47) | USP2USP8ACLYAVPR2GPR27 | |
| SCHEMBL23141388 | 0.90 | USP2 (0.47) | USP2USP8ACLYAVPR2GPR27 | |
| SCHEMBL23877605 | 0.80 | USP2 (0.49) | CYP2C9CYP2C19USP2USP8AVPR2 | |
| SCHEMBL23877572 | 0.79 | USP2 (0.49) | USP2USP8ACLYAVPR2GPR27 | |
| SCHEMBL23877434 | 0.78 | AVPR2 (0.42) | METAP2USP2USP8AVPR2GPR27 | |
| SCHEMBL23879533 | 0.77 | ACLY (0.36) | CYP2C9CYP2C19METAP2MCL1ACLY | |
| SCHEMBL23877582 | 0.77 | USP2 (0.47) | USP2USP8ACLYAVPR2GPR27 | |
| SCHEMBL23877634 | 0.77 | KDM1A (0.47) | FFAR4CCR9USP2USP8ACLY | |
| SCHEMBL23877456 | 0.76 | HSD17B2 (0.42) | CCR9MCL1USP2USP8ACLY | |
| SCHEMBL23877465 | 0.76 | USP2 (0.47) | USP2USP8ACLYAVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | CYP2C9 443/4885CYP2C19 172/4885FFAR4 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.